, Inc. (ADR) (BIDU) Feeds the Bad News Bears – Qihoo 360 Technology Co Ltd (QIHU), Groupon Inc (GRPN)

Page 1 of 2

Baidu (BIDU)The bears are piling up onĀ, Inc. (ADR) (NASDAQ:BIDU) .

A whopping 10.6 million shares were sold short as of mid-February according to Nasdaq’s latest bi-monthly update. This is nearly twice the number of bearish wagers that were placed on China’s leading search engine a year ago. Baidu’s short interest hadn’t topped 9 million over the past year until now.

The worrywarts appear to be right — for now.

February wasn’t a good month for, Inc. (ADR) (NASDAQ:BIDU). The shares surrendered 16% of their value last month. A poorly received quarterly report early in the month didn’t help, and concerns about Qihoo 360 Technology Co Ltd (NYSE:QIHU) gaining ground since rolling out its own search platform last summer continue to linger.

Qihoo 360 reports tomorrow, and it could ding, Inc. (ADR) (NASDAQ:BIDU) if it has some encouraging metrics to offer up on its nascent search initiatives.

This doesn’t mean that there aren’t a lot of things working in Baidu’s favor here.

  • Baidu’s claims of Qihoo infringement — alleging that Qihoo is crawling and copying Baidu’s content — is gaining legal steam in a Beijing court.
  • The dot-com speedster now claims to be serving up 5 billion search queries a day across search, community, and partner sites.
  • Groupon Inc (NASDAQ:GRPN)‘s recent failures have soured companies on daily deals sites, but that didn’t stop Baidu from rolling out a second group-buying portal last month. Groupon may be shocking the market with its red ink, but at least Baidu’s profitability has remained intact as it diversifies its model.

Then we get to Baidu’s valuation.

Baidu’s stock may be trading 44% below its all-time peak two summers ago, but the Chinese Internet bellwether is still growing at a healthy clip. The end result is that Baidu is now fetching just 17 times this year’s projected profitability and less than 14 times next year’s target.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!